医药行业周报：AI有望赋能医疗领域，继续看好创新药+创新药产业链

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology sector [1] Core Views - The pharmaceutical sector has seen a decline in holdings to historical lows, but there is continued optimism for innovative drugs and their industrial chain [2] - The AI field is gaining attention, with significant potential for application in healthcare, projected to grow from $4.2 billion in 2020 to $34.5 billion by 2027, representing a CAGR of 35.1% [4][15] - The report emphasizes the importance of identifying companies with quality data access and a broad user base in the AI+medical field [4][20] Summary by Sections 1. Weekly Pharmaceutical Sector Performance - From February 3 to February 7, 2025, the pharmaceutical sector outperformed the CSI 300 index, rising by 3.21% compared to the index's 1.98% increase [4][6] - The sector's valuation as of February 7, 2025, stands at 26.08 times PE, with a premium of 118.48% over the CSI 300 [7] 2. Industry Events and Policy Overview - The National Healthcare Security Administration announced innovations in settlement methods to ensure timely payments to medical institutions [14] - The rapid development of AI technology is being integrated into various sectors, including healthcare, enhancing efficiency and service delivery [14] 3. Industry Investment Strategy - The report suggests focusing on sectors with good growth potential and industrial logic, particularly innovative drugs and the medical device sector, which is expected to improve in 2025 [24][25] - The report highlights the importance of internationalization and innovation in the pharmaceutical industry, with a focus on companies that can leverage these trends [25][26] 4. Recommended Stocks - Recommended stocks include: - Hengrui Medicine: Expected to see growth from innovative drugs and international expansion [34] - Innovent Biologics: Anticipated to enter a rapid growth phase with several products expected to launch [32] - WuXi AppTec: A leading integrated CXO service provider with strong growth in orders and revenue [36] - Aibot Medical: A high-growth ophthalmic device platform benefiting from market expansion [36] - Tongrentang: A classic Chinese medicine brand expected to improve operational efficiency [38]